Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
In systemic lupus erythematosus (SLE), adaptive immunity is activated by the stimulation of innate immunity, leading to the development of autoreactive T cells and activation and differentiation of B cells. Cytokine signalling plays an essential role in the pathogenesis and progression of this disea...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/4/e005072.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543274518544384 |
|---|---|
| author | Yoshiya Tanaka Shingo Nakayamada Yurie Satoh-Kanda |
| author_facet | Yoshiya Tanaka Shingo Nakayamada Yurie Satoh-Kanda |
| author_sort | Yoshiya Tanaka |
| collection | DOAJ |
| description | In systemic lupus erythematosus (SLE), adaptive immunity is activated by the stimulation of innate immunity, leading to the development of autoreactive T cells and activation and differentiation of B cells. Cytokine signalling plays an essential role in the pathogenesis and progression of this disease. In particular, the differentiation and function of CD4+ T cell subsets, which play a central role in SLE pathology, are significantly altered by cytokine stimulation. Many cytokines transmit signals via the Janus-activated kinase (JAK)-STAT pathway, but there is no one-to-one correspondence between cytokine receptors and JAK/TYK2. Multiple cytokines activate JAK/TYK2, and multiple JAK/TYK2 molecules are simultaneously activated by a single cytokine. Therefore, the modulation of the JAK-STAT pathway has the potential to control immune responses in SLE. Although several JAK/TYK2 inhibitors are currently undergoing clinical trials, more selective drugs that can target cytokine signals according to the specific pathology of the disease are required. TYK2 inhibitors, which are involved in the signal transduction of type I interferon and interleukin-12/23 pathways and are linked to disease susceptibility genes in SLE, may have the potential to fine-tune the differentiation and function of immune cells, particularly CD4+ T cells. |
| format | Article |
| id | doaj-art-9e6a01f18624426e9449ac416c0cefb3 |
| institution | Kabale University |
| issn | 2056-5933 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-9e6a01f18624426e9449ac416c0cefb32025-01-13T15:20:11ZengBMJ Publishing GroupRMD Open2056-59332024-12-0110410.1136/rmdopen-2024-005072Fine-tuning SLE treatment: the potential of selective TYK2 inhibitionYoshiya Tanaka0Shingo Nakayamada1Yurie Satoh-Kanda2The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, JapanThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JapanThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JapanIn systemic lupus erythematosus (SLE), adaptive immunity is activated by the stimulation of innate immunity, leading to the development of autoreactive T cells and activation and differentiation of B cells. Cytokine signalling plays an essential role in the pathogenesis and progression of this disease. In particular, the differentiation and function of CD4+ T cell subsets, which play a central role in SLE pathology, are significantly altered by cytokine stimulation. Many cytokines transmit signals via the Janus-activated kinase (JAK)-STAT pathway, but there is no one-to-one correspondence between cytokine receptors and JAK/TYK2. Multiple cytokines activate JAK/TYK2, and multiple JAK/TYK2 molecules are simultaneously activated by a single cytokine. Therefore, the modulation of the JAK-STAT pathway has the potential to control immune responses in SLE. Although several JAK/TYK2 inhibitors are currently undergoing clinical trials, more selective drugs that can target cytokine signals according to the specific pathology of the disease are required. TYK2 inhibitors, which are involved in the signal transduction of type I interferon and interleukin-12/23 pathways and are linked to disease susceptibility genes in SLE, may have the potential to fine-tune the differentiation and function of immune cells, particularly CD4+ T cells.https://rmdopen.bmj.com/content/10/4/e005072.full |
| spellingShingle | Yoshiya Tanaka Shingo Nakayamada Yurie Satoh-Kanda Fine-tuning SLE treatment: the potential of selective TYK2 inhibition RMD Open |
| title | Fine-tuning SLE treatment: the potential of selective TYK2 inhibition |
| title_full | Fine-tuning SLE treatment: the potential of selective TYK2 inhibition |
| title_fullStr | Fine-tuning SLE treatment: the potential of selective TYK2 inhibition |
| title_full_unstemmed | Fine-tuning SLE treatment: the potential of selective TYK2 inhibition |
| title_short | Fine-tuning SLE treatment: the potential of selective TYK2 inhibition |
| title_sort | fine tuning sle treatment the potential of selective tyk2 inhibition |
| url | https://rmdopen.bmj.com/content/10/4/e005072.full |
| work_keys_str_mv | AT yoshiyatanaka finetuningsletreatmentthepotentialofselectivetyk2inhibition AT shingonakayamada finetuningsletreatmentthepotentialofselectivetyk2inhibition AT yuriesatohkanda finetuningsletreatmentthepotentialofselectivetyk2inhibition |